KR920703513A - 단백질 활성효소 c(protein kinase c)를 방해하는 비스-(하이드록시알킬아미노)-안트라퀴논 - Google Patents

단백질 활성효소 c(protein kinase c)를 방해하는 비스-(하이드록시알킬아미노)-안트라퀴논

Info

Publication number
KR920703513A
KR920703513A KR1019920701572A KR920701572A KR920703513A KR 920703513 A KR920703513 A KR 920703513A KR 1019920701572 A KR1019920701572 A KR 1019920701572A KR 920701572 A KR920701572 A KR 920701572A KR 920703513 A KR920703513 A KR 920703513A
Authority
KR
South Korea
Prior art keywords
alkyl
independently
aryl
independent
compound
Prior art date
Application number
KR1019920701572A
Other languages
English (en)
Inventor
비이. 지앙 잭
조지 존슨 매리
Original Assignee
클레이턴 아이. 턴칸
스핑크스 파마슈티칼스, 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/609,252 external-priority patent/US5204370A/en
Application filed by 클레이턴 아이. 턴칸, 스핑크스 파마슈티칼스, 코포레이션 filed Critical 클레이턴 아이. 턴칸
Publication of KR920703513A publication Critical patent/KR920703513A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/36—Compounds containing oxirane rings with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/24—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings
    • C07C225/26—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings
    • C07C225/32—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings of condensed quinone ring systems formed by at least three rings
    • C07C225/34—Amino anthraquinones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/24—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings
    • C07C225/26—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings
    • C07C225/32—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings of condensed quinone ring systems formed by at least three rings
    • C07C225/34—Amino anthraquinones
    • C07C225/36—Amino anthraquinones the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/68—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
    • C07C229/72—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the carbon skeleton being further substituted by doubly-bound oxygen atoms
    • C07C229/74—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the carbon skeleton being further substituted by doubly-bound oxygen atoms the condensed ring system being formed by at least three rings, e.g. amino anthraquinone carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/30—Isothioureas
    • C07C335/32—Isothioureas having sulfur atoms of isothiourea groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/24—Anthracenes; Hydrogenated anthracenes

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

단백질 활성효소 C(PROTEIN KINASE C)를 방해하는 비스-(하이드록시알킬아미노)-안트라퀴논
[도면의 간단한 설명]
제1도는 본 발명의 화합물의 합성에 이용되는 도표 I의 합성 루트를 보여준다.
제2도는 본 발명의 화합물의 합성에 이용되는 도표 II의 합성 루트를 보여준다.
제3도는 본 발명의 화합물의 합성에 이용되는 도표 III의 합성 루트를 보여준다.
제4도는 대조구의 MCF-7종양무게와 화합물 1b-1로 처리된 생쥐(mice)대 날마다의 이식 종양의 평균값에 대한 그래프를 보여준다. 생쥐 대조구용의 종양 크기는 검은 원이다; 시험된 생쥐의 종양무게는 검은 사각형이다.
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (13)

  1. 하기의 식을 가지는 치환 안트라퀴논
    식에서 R1과 R2는 독립적인 H, C1-C10알킬, 아릴, 아릴알킬, 알킬아릴, 또는 질소를 포함하는 부가적인 헤테로원자들을 함유하는 치환되거나 치환되지 않은 사이클릭 링(cyclic ring)을 형성하는 주위의 질소 원자를 가지는 R1과 R2; m과 n은 독립적인 1,2 또는 3; A는 할로겐, OH, 알콕시, OCO(NR3R4), S-C(NH2)=NR5, 또는 m=1일때 부가적인 산소원자를 갖는 옥시란 링(oxiran ring); R3, R4, 및 R5는 독립적으로 H, 알킬, 또는 아릴; X는 H, OH, NR6R7, Cl, Br, I, F, 알킬, 아릴, 알콕시, 아릴록시, COOR8또는 CONR9R10; 그리고 R6, R7, R8, R9및 R10은 독립적인 H, 저가 알킬 또는 아릴인 것을 특징으로 하는 치환 안트라퀴논.
  2. 제1항에 있어서, R1과 R2는 독립적으로 H, 또는 저가 알킬; m 과 n은 독립적인 1, 또는 2; A는 할로겐, OCO(NR3R4), S-C(NH2)=NR5, 또는 m=1일때 부가적인 산소원자를 갖는 옥시란 링(oxiran ring); R3, R4, 및 R5는 독립적으로 H, 또는 알킬; X는 H, OH, Cl, Br, I, F 또는 알콕시인 것을 특징으로 하는 치환 안트라퀴논.
  3. 제2항에 있어서, R1과 R2는 독립적으로 H, 또는 아릴알킬; m과 n은 1;A는 Cl, Br, OCO(NR3R4), S-C(NH2)=NR5또는 m=1일때 부가적인 산소원자를 갖는 옥시란 링(oxiran ring); R3, R4및 R5는 독립적으로 H; X는 H, OH인 것을 특징으로 하는 치환 안트라퀴논.
  4. 제1항의 치환된 안트라퀴논으로 구성되는 단백질 활성효소 C를 방해하는 약제적 조성물과 약제적으로 수용가능한 운반체 또는 희석제.
  5. 제2항의 치환된 안트라퀴논으로 구성되는 단백질 활성효소 C를 방해하는 약제적 조성물과 약제적으로 수용가능한 운반체 또는 희석제.
  6. 제3항의 치환된 안트라퀴논으로 구성되는 단백질 활성효소 C를 방해하는 약제적 조성물과 약제적으로 수용가능한 운반체 또는 희석제.
  7. 하기식으로 이루어지는 치환된 안트라퀴논의 방해량을 가지는 단백질 활성 효소 C와 접촉하는 것으로 구성된 단백질 활성 효소 C의 방해 방법.
    식에서 R1과 R2는 독립적인 H, C1-C10알킬, 아릴, 아릴알킬, 알킬아릴, 또는 질소를 포함하는 부가적인 헤테로원자들을 함유하는 치환되거나 치환되지 않은 사이클릭 링(cyclic ring)을 형성하는 주위의 질소 원자를 가지는 R1과 R2; m과 n은 독립적인 1,2 또는 3; A는 할로겐, OH, 알콕시, OCO(NR3R4), S-C(NH2)=NR5, 또는 m=1일때 부가적인 산소원자를 갖는 옥시란 링(oxiran ring); R3, R4, 및 R5는 독립적으로 H, 알킬, 또는 아릴; X는 H, OH, NR6R7, Cl, Br, I, F, 알킬, 아릴, 알콕시, 아릴록시, COOR8또는 CONR9R10; 그리고 R6, R7, R8, R9및 R10은 독립적인 H, 저가 알킬 또는 아릴인 것을 특징으로 하는 치환 안트라퀴논을 이용한 단백질 활성효소 C의 방해방법.
  8. 제7항에 있어서, 상기한 식의 화합물의 R1과 R2는 독립적으로 H, 또는 저가 알킬; m과 n은 독립적인 1, 또는 2; A는 할로겐, OCO(NR3R4), S-C(NH2)=NR5, 또는 m=1일때 부가적인 산소원자를 갖는 옥시란 링(oxiran ring); R3, R4, 및 R5는 독립적으로 H, 또는 알킬; X는 H, OH, Cl, Br, I, F 또는 알콕시인 것을 특징으로 하는 치환 안트라퀴논을 이용한 단백질 활성효소 C의 방해방법.
  9. 제8항에 있어서, 상기한 식의 화합물의 R1과 R2는 독립적으로 H, 또는 저가 알킬; m과 n은 1; A는 Br, Cl, OCO(NR3R4), S-C(NH2)=NR5또는 m=1일때 부가적인 산소원자를 갖는 옥시란 링(oxiran ring); R3, R4및 R5는 독립적으로 H; X는 H, 또는 OH인 것을 특징으로 하는 치환 안트라퀴논을 이용한 단백질 활성효소의 C의 방해방법.
  10. 하기 식의 화합물을 이용하여
    식에서 R1과 R3는 독립적인 H, C1-C10알킬, 아릴, 아릴알킬, 알킬아릴, 또는 질소를 포함하는 부가적인 헤테로원자들을 함유하는 치환되거나 치환되지 않은 사이클릭 링(cyclic ring)을 형성하는 주위의 질소 원자를 가지는 R1과 R2; m과 n은 독립적인 1,2 또는 3; A는 할로겐, OH, 알콕시, OCO(NR3R4), S-C(NH2)=NR5, 또는 m=1일때 부가적인 산소원자를 갖는 옥시란 링(oxiran ring); R3, R4, 및 R5는 독립적으로 H, 알킬, 또는 아릴; X는 H, OH, NR6R7, Cl, Br, I, F, 알킬, 아릴 알콕시, 아릴록시, COOR8, 또는 CONR9R10; 그리고 R6, R7, R8, R9및 R10은 독립적인 H, 저가 알킬 또는 아릴을 단백질 활성효소 C용의 약제의 준비에 이용하는 것을 특징으로 하는 치환 안트라퀴논.
  11. 제10항에 있어서, 식에서 R1과 R2는 독립적으로 H, 또는 저가 알킬; m과 n은 독립적인 1, 또는 2; A는 할로겐, OCO(NR3R4), S-C(NH2)=NR5, 또는 m=1일때 부가적인 산소원자를 갖는 옥시란 링(oxiran ring); R3, R4, 및 R5는 독립적으로 H, 또는 알킬; X는 H, OH, Cl, Br, I, F 알콕시를 이용하는 것을 특징으로 하는 치환 안트라퀴논.
  12. 제11항에 있어서, 식에서 R1과 R2는 저가 알킬; m과 n은 1; A는 Cl, Br, OCO(NR3R4), S-C(NH2)=NR5또는 m=1일때 부가적인 산소원자를 갖는 옥시란 링(oxiran ring); R3, R4및 R5는 H; X는 H, 또는 OH를 이용하는 것을 것을 특징으로 하는 치환 안트라퀴논.
  13. 제10항에 있어서, 상기 화합물은 치료적인 양 내에서 약제 내에 존재하는 것을 특징으로 하는 치환 안트라퀴논.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920701572A 1990-11-02 1991-10-30 단백질 활성효소 c(protein kinase c)를 방해하는 비스-(하이드록시알킬아미노)-안트라퀴논 KR920703513A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US60917990A 1990-11-02 1990-11-02
US609,179 1990-11-02
US07/609,252 US5204370A (en) 1990-11-05 1990-11-05 Bis-(hydroxyalkylamino)-anthraquinone inhibitors of protein kinase C
US609,252 1990-11-05
PCT/US1991/008026 WO1992007557A1 (en) 1990-11-02 1991-10-30 Bis-(hydroxyalkylamino)-anthraquinone inhibitors of protein kinase c

Publications (1)

Publication Number Publication Date
KR920703513A true KR920703513A (ko) 1992-12-18

Family

ID=27085973

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920701572A KR920703513A (ko) 1990-11-02 1991-10-30 단백질 활성효소 c(protein kinase c)를 방해하는 비스-(하이드록시알킬아미노)-안트라퀴논

Country Status (9)

Country Link
US (1) US5344841A (ko)
EP (1) EP0507938A4 (ko)
JP (1) JPH05503721A (ko)
KR (1) KR920703513A (ko)
AU (1) AU637014B2 (ko)
BR (1) BR9106118A (ko)
CA (1) CA2072889A1 (ko)
HU (1) HUT64295A (ko)
WO (1) WO1992007557A1 (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141957A (en) * 1990-11-02 1992-08-25 Sphinx Pharmaceuticals Corporation 1,4-bis-(amino-hydroxyalkylamino)-anthraquinones for inhibiting protein kinase c
GB9205859D0 (en) * 1992-03-18 1992-04-29 Imp Cancer Res Tech Compounds
US5519035A (en) * 1993-07-02 1996-05-21 Cornell Research Foundation, Inc. Treatment of stroke or in anticipation of the occurrence of brain ischemia
GB9320191D0 (en) * 1993-09-30 1993-11-17 Univ Napier Compounds
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
US6232299B1 (en) * 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
US6717030B2 (en) * 1998-07-06 2004-04-06 The Regents Of The University Of California Protein kinase C epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse
US6376467B1 (en) * 1998-10-09 2002-04-23 The Regents Of The University Of California Use of inhibitors of protein kinase C epsilon to treat pain
GB2403474B (en) * 2002-04-18 2006-10-11 Inst Med Molecular Design Inc Amide derivatives
DE10244453A1 (de) * 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
NZ574520A (en) * 2002-11-27 2011-02-25 Dmi Biosciences Inc Use of casein which is at least 10% dephosphorylated for the treatment of diseases and conditions mediated by increased phosphorylation
EP1670497A4 (en) 2003-09-16 2009-07-15 Garvan Inst Med Res METHODS OF IDENTIFYING C-EPSILON PROTEIN KINASE (PKC ™) MODULATORS AND METHOD FOR TREATING ABERRANT GLUCOSE METABOLISM THEREOF
EP1877424A4 (en) * 2005-04-11 2010-09-29 Pharmagap Inc INHIBITORS OF PROTEIN KINASES AND USES THEREOF
AU2008206028A1 (en) 2007-01-19 2008-07-24 Kai Pharmaceuticals, Inc. Methods of use of epsilon inhibitor compounds for the attenuation of pain
DE102007063056A1 (de) * 2007-12-28 2009-07-02 Universität Leipzig Verwendung von 4-Amino-1,3,8-trihydroxyanthracen-9,10-dionderivaten zur Inhibierung von Proteinkinasen
US20120208750A1 (en) 2009-09-29 2012-08-16 Joslin Diabetes Center, Inc. Use of protein kinase c delta (pkcd) inhibitors to treat diabetes, obesity, and hepatic steatosis
CA2848726C (en) 2011-08-19 2019-09-10 Emory University Bax agonist, compositions, and methods related thereto
AU2015256266B2 (en) * 2014-05-05 2019-01-17 Emory University BH4 antagonists and methods related thereto
CN104491889B (zh) * 2014-12-05 2017-05-24 江苏省中医药研究院 放射性同位素标记的单蒽核蒽醌类化合物在制备用于检测心肌活性的药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1540733A (en) * 1923-10-25 1925-06-02 British Dyestuffs Corp Ltd Dyestuffs of the anthraquinone series
US2411148A (en) * 1943-10-23 1946-11-19 Eastman Kodak Co Anthraquinone dyestuffs
US3960751A (en) * 1973-09-19 1976-06-01 Matsushita Electric Industrial Co., Ltd. Electro-optical display element
US4197249A (en) * 1977-08-15 1980-04-08 American Cyanamid Company 1,4-Bis(substituted-amino)-5,8-dihydroxyanthraquinones and leuco bases thereof
US4310666A (en) * 1978-04-10 1982-01-12 United States Of America Anti-neoplastic 1,4-bis-(substituted aminoalkyl amino)-anthraquinones
US4526989A (en) * 1978-07-11 1985-07-02 American Cyanamid Company 1,4-Bis (substituted-amino)-5,8-dihydroxy-anthraquinones and leuco bases thereof
EP0079862B1 (de) * 1981-11-18 1986-01-15 Ciba-Geigy Ag 1,4-Diaminoanthrachinonverbindungen
US4540788A (en) * 1983-07-14 1985-09-10 American Cyanamid Company Schiff bases of [(aminoalkyl or substituted aminoalkyl)amino]-9,10-anthracenediones
DE3331296A1 (de) * 1983-08-31 1985-03-14 Hoechst Ag, 6230 Frankfurt Mono- und bisfunktionelle anthrachinon-(oxy-2,3-oxidopropane), verfahren zu ihrer herstellung und ihre verwendung
US4894451A (en) * 1985-04-01 1990-01-16 The University Of Vermont Unsymmetrical 1,4-bis(aminoalkylamino)-anthracene-9, 10-diones and derivatives
JPS6315853A (ja) * 1986-07-07 1988-01-22 Dainippon Printing Co Ltd 熱転写シ−ト用染料
US4816450A (en) * 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
JPH0219819A (ja) * 1988-07-08 1990-01-23 Nikon Corp 角度制御装置
DE3827974A1 (de) * 1988-08-18 1990-02-22 Boehringer Mannheim Gmbh Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen

Also Published As

Publication number Publication date
US5344841A (en) 1994-09-06
BR9106118A (pt) 1993-03-02
AU9039891A (en) 1992-05-26
WO1992007557A1 (en) 1992-05-14
HUT64295A (en) 1993-12-28
CA2072889A1 (en) 1992-05-03
AU637014B2 (en) 1993-05-13
JPH05503721A (ja) 1993-06-17
EP0507938A1 (en) 1992-10-14
EP0507938A4 (en) 1993-03-10

Similar Documents

Publication Publication Date Title
KR920703513A (ko) 단백질 활성효소 c(protein kinase c)를 방해하는 비스-(하이드록시알킬아미노)-안트라퀴논
AU4306796A (en) Novel 3,5-dioxo-(2h,4h)-1,2,4-triazine derivatives, their preparation and use as drugs
DK162519C (da) Dihydropyridazinonderivater og fremgangsmaade til fremstilling deraf samt farmaceutisk praeparat indeholdende forbindelserne
KR920703512A (ko) 단백질 활성효소 c(protein kinase c)를 방해하는 1, 4-비스-(아미노-하이드록시알킬아미노)-안트라퀴논
SE7501365L (ko)
GB1275525A (en) Ureidophenyguanidines, process for their preparation, and their fungicidal use
ES2033279T3 (es) Procedimiento para preparar un compuesto a base de quinolina.
JPS5543077A (en) Preparation of 1,3-dithiolan-2-ylidenemalonate derivative
WO1988003142A3 (en) 7-deazaguanines as immunomodulators
ES8308835A1 (es) Un procedimiento para la preparacion de derivados de etanola-mina.
ES8202818A1 (es) Un procedimiento para preparar derivados de tetrazolilcuma- rina
ES543802A0 (es) Procedimiento de preparacion de nuevos derivados a-etilben- zol con un grupo n-carbamiloxi sustituido
JPS5225765A (en) Preparation of novel isoindoline derivatives
JPS55120575A (en) Cis-2,3-epoxy-4-lower alkoxyphenylbutanoic acid derivative and its production
GB1421305A (en) 1,4-dihydroquinoline derivatives their production and their medicinal use
JPS5278888A (en) Synthesis of novel quinazoline derivatives
JPS525767A (en) Preparation of novel organic compounds
JPS5273873A (en) Synthesis of carbostryl derivatives
JPS5273874A (en) Synthesis of dihydrocarbostyril derivatives
JPS5251366A (en) Preparation of bispyrazolon derivatives
AU586089B2 (en) Phosphodiesterace type 111 inhibitors having a thiadiazinone ring as part of a tricyclic structure
JPS5246083A (en) Preparation of 3-amino-4-hyaroxycarbostyrils
CS9000882A3 (en) Novel n-hydroxytriazole derivatives, process for their preparation and fungicides comprising them as an active component
JPS5262245A (en) Preparation of novel cyclopropylmethylamine derivatives
JPS5251382A (en) Preparation of novel morpholine derivatives and acid addiio salts ther eof

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application